---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-25-000098"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:28:42.964168+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evolent reaffirms FY2025 Adj. EBITDA guidance $135-165M; secures Ares non-dilutive financing

## Summary
- Reaffirmed FY2025 Adj. EBITDA guidance $135-165M and Q2 2025 guidance $33-40M.
- Oncology cost trend below expectations through May; if continues, expects Q2 Adj. EBITDA in top half of range.
- Secured Commitment Letter with Ares for Incremental Facility to retire 2025 Convertible Notes; non-dilutive debt option.
- Amendment No. 5 to Credit Agreement modifies liquidity test, adds default if Exchange not consummated.
- Accelerating organic new revenue bookings forecast for 2026 go-lives due to high market demand.

## SEC filing metadata
- accession: 0001628908-25-000098
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890825000098/0001628908-25-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890825000098/evh-20250619.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-25-000098
- JSON: https://secwatch.observer/filing/0001628908-25-000098.json
- Plain text: https://secwatch.observer/filing/0001628908-25-000098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.